House Committee Asks Pfizer To Explain Celebrex Safety Defense
This article was originally published in The Pink Sheet Daily
Executive Summary
The House Energy & Commerce Committee is asking Pfizer to justify claims it made about Celebrex' safety profile following the withdrawal of Merck's Vioxx